Lv1
46 积分 2022-10-17 加入
Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia
28天前
已关闭
A First-in-Class JAK/ROCK Inhibitor, Rovadicitinib, for Glucocorticoid-Refractory or -Dependent Chronic GVHD
28天前
已关闭
A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma
1个月前
已完结
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
1个月前
已完结
PD-1 or PD-L1—A Difference That Makes No Difference?
1个月前
已完结
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer The GEMSTONE-303 Randomized Clinical Trial
1个月前
已完结
Real-World Evidence of Relapsed/Refractory Mantle Cell Lymphoma Patients and Treatments: A Systematic Review
1个月前
已完结
High-Risk MCL: Recognition and Treatment
1个月前
已完结
皖公网安备34019202002308
